Parkinson's disease (PD) is a common neurodegenerative disorder, affecting about one percent of the population over the age of 60 years. While the typical age at onset is in the sixth decade of life ...

The company’s lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It has various small molecule drug candidates ...

Parkinson's disease is a progressive neurodegenerative disorder, which is characterized by motor symptoms such as tremor, rigidity, slowness of movement and problems with gait. Motor symptoms are ...